Understanding Growth Hormone Secretagogues: CJC-1295, Ipamorelin & More

What Are Growth Hormone Secretagogues?

Growth hormone secretagogues (GHS) are a class of compounds that stimulate the pituitary gland to produce and release growth hormone (GH). Unlike exogenous growth hormone, which introduces synthetic GH directly, secretagogues work by amplifying the body's natural GH production pathways. This distinction is crucial for research, as it means GH release follows natural pulsatile patterns rather than creating a sustained, supraphysiological level.

GHRH Analogs: CJC-1295 and Modified GRF (1-29)

Growth Hormone Releasing Hormone (GHRH) analogs mimic the action of endogenous GHRH, which signals the pituitary to release stored growth hormone. CJC-1295 is a synthetic GHRH analog with a 30-amino-acid chain that has been modified for extended half-life. It comes in two primary forms for research: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also known as Modified GRF (1-29).

CJC-1295 with DAC binds to albumin in the bloodstream, extending its half-life to approximately 6-8 days. This creates a sustained elevation in GH levels. Modified GRF (1-29), without the DAC component, has a shorter half-life of approximately 30 minutes and produces more acute GH pulses that more closely mimic natural secretion patterns.

• CJC-1295 with DAC: Extended half-life, sustained GH elevation, less frequent administration in research protocols
• Modified GRF (1-29): Shorter half-life, pulsatile GH release, often paired with a GHRP

Ghrelin Mimetics: Ipamorelin, GHRP-6, and GHRP-2

Growth Hormone Releasing Peptides (GHRPs) work through a different pathway, acting on the ghrelin receptor (GHS-R) to stimulate GH release. Ipamorelin is considered one of the most selective GHRPs, producing a strong GH pulse without significantly affecting cortisol or prolactin levels. This selectivity makes it particularly valuable in research settings where confounding hormonal changes need to be minimized.

GHRP-6 and GHRP-2 are older but well-studied ghrelin mimetics. GHRP-6 is known for its strong appetite-stimulating effects and robust GH release, while GHRP-2 offers a potent GH pulse with moderate appetite stimulation. Both can elevate cortisol and prolactin at higher doses, a consideration for research protocol design.

MK-677 (Ibutamoren): The Oral Secretagogue

MK-677, also known as Ibutamoren, is a non-peptide ghrelin mimetic that can be administered orally. It has a long half-life of approximately 24 hours and produces sustained elevations in GH and IGF-1 levels. Research has explored its potential applications in age-related GH decline, muscle wasting, sleep quality, and bone density. Its oral bioavailability sets it apart from injectable peptide secretagogues.

Synergistic Combinations in Research

One of the most studied approaches in GHS research is the combination of a GHRH analog with a GHRP. The rationale is that GHRH analogs and GHRPs work through complementary pathways, and their combined use produces a synergistic GH release that exceeds the sum of their individual effects. The CJC-1295 (no DAC) plus Ipamorelin combination is one of the most commonly referenced pairings in current research literature.